Akari Therapeutics (AKTX) Other Accumulated Expenses (2022 - 2026)

Akari Therapeutics has disclosed Other Accumulated Expenses across 5 years of filings, most recently posting $505000.0 for Q1 2026.

• Other Accumulated Expenses for Q1 2026 came in at $505000.0, down 36.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $505000.0 (down 36.56% YoY), and the FY2025 annual result was $449000.0, down 38.58% from the prior year.
• Other Accumulated Expenses came in at $505000.0 for Q1 2026 at Akari Therapeutics, up from $449000.0 in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $983000.0 in Q1 2024 to a low of $41000.0 in Q2 2024.
• The 5-year median for Other Accumulated Expenses is $449000.0 (2025), against an average of $429545.5.
• Peak annual rise in Other Accumulated Expenses reached 1485.37% in 2025, while the deepest fall reached 73.1% in 2025.
• Akari Therapeutics' Other Accumulated Expenses stood at $94000.0 in 2022, then declined by 20.21% to $75000.0 in 2023, then surged by 874.67% to $731000.0 in 2024, then sank by 38.58% to $449000.0 in 2025, then increased by 12.47% to $505000.0 in 2026.
• The last three Other Accumulated Expenses figures came in at $505000.0 (Q1 2026), $449000.0 (Q4 2025), and $85000.0 (Q3 2025), per Business Quant data.